Literature DB >> 10623795

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

D R Surman1, M E Dudley, W W Overwijk, N P Restifo.   

Abstract

Neoantigens resulting from the inherent genomic instability of tumor cells generally do not trigger immune recognition. Similarly, transfection of tumors with model Ags often fails to elicit CD8+ T cell responses or alter a tumor's growth rate or lethality. We report here that the adoptive transfer of activated Th1-type CD4+ T cells specific for a model tumor Ag results in the de novo generation of CD8+ T cells with specificity to that Ag and concomitant tumor destruction. The anti-tumor effects of the CD4+ T cells required the presence of both MHC class I and class II on host cells, as evidenced by experiments in knockout mice, suggesting that CD4+ T cells enhanced the ability of host APC to activate endogenous CD8+ T cells. These results indicate that the apparent inability of tumor cells expressing highly immunogenic epitopes to activate tumor-specific CD8+ T cells can be altered by activated CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623795      PMCID: PMC2239008          DOI: 10.4049/jimmunol.164.2.562

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

2.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

Authors:  J P Ridge; F Di Rosa; P Matzinger
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

3.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Authors:  W W Overwijk; D S Lee; D R Surman; K R Irvine; C E Touloukian; C C Chan; M W Carroll; B Moss; S A Rosenberg; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 4.  Genetic instabilities in human cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

5.  T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.

Authors:  W Böhm; S Thoma; F Leithäuser; P Möller; R Schirmbeck; J Reimann
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

6.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

Review 7.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.

Authors:  S A Kalams; B D Walker
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

8.  Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.

Authors:  F Ossendorp; E Mengedé; M Camps; R Filius; C J Melief
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

9.  CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity.

Authors:  C Kurts; F R Carbone; M Barnden; E Blanas; J Allison; W R Heath; J F Miller
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Authors:  W W Overwijk; A Tsung; K R Irvine; M R Parkhurst; T J Goletz; K Tsung; M W Carroll; C Liu; B Moss; S A Rosenberg; N P Restifo
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  48 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 2.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 3.  CD4 T-cell immunotherapy for chronic viral infections and cancer.

Authors:  Alice O Kamphorst; Rafi Ahmed
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

4.  Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Authors:  Yangbing Zhao; Zhili Zheng; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

Review 5.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 6.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Authors:  Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

9.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

10.  Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Authors:  Sung Hee Yoon; Sun Ok Yun; Jung Yong Park; Hee Yeun Won; Eun Kyung Kim; Hyun Jung Sohn; Hyun Il Cho; Tai Gyu Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.